About Bios Partners
Bios Partners is a venture capital firm founded in 2014. It is primarily based out of Fort Worth, United States. As of Sep 2024, Bios Partners has invested in 16 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series D round of ONL Therapeutics Overall, Bios Partners portfolio has seen 7 IPOs and 2 acquisitions including key companies like Taysha Gene Therapies, Lantern Pharma and Cognition Therapeutics. A lot of funds co-invest with Bios Partners, with names like DEFTA Partners sharing a substantial percentage of its portfolio. Bios Partners has team of 10 people including 5 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 1 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Bios Partners' List of Top Investments
Bios Partners has a portfolio of 16 companies. Their most notable investments are in Azitra and Azitra.Their portfolio spans across and United States. They have invested in Life Sciences, High Tech, Enterprise Applications and 2 other sectors, across stages such as Series A, Series B and 1 more. Here is the list of top investments by Bios Partners:1. 410 Medical
Provider of rapid infusion system for critically ill patients. The company's products include "LifeFlow Fluid Infuser", which allows healthcare providers to deliver fluids quickly and efficiently to critically ill patients.
Key facts about 410 Medical
- Founded Year: 2012
- Location: Durham (United States)
- Stage: Series B
- Total Funding till date: $78M
- Employee Count: 61 as on Aug 31, 2026
- Investors: CU Healthcare Innovation Fund, Bios Partners and 20 Others
- Latest Funding Round: Series B, Jun 30, 2026, $*****
- Highlight: Editors' Pick
Developer of gene-based therapies for treating CNS disorders. The company has developed an AAV9 capsid delivery system and Zolgensma is a gene-based therapy to treat CNS diseases. The pipeline includes TGTX-104, gene replacement therapy to treat Rett Syndrome (IND enabling), TGTX-106, short hairpin RNA, to treat Angelman, and more.
Key facts about Taysha Gene Therapies
- Founded Year: 2020
- Location: Dallas (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $125M
- Employee Count: 136 as on Aug 31, 2026
- Investors: Venrock, RTW Investments and 20 Others
- Latest Funding Round: Post IPO, Aug 14, 2023, $*****
- Highlight: Public
Developing drug and companion diagnostics for multi-drug resistant cancers. Its approach is to biomarker-biased genetic screening to identify and treat patients that would benefit most from our drugs. Its lead candidate is Irovfulven-1, a new class of anti-tumor agents to treat multi-drug-resistant cancers.
Key facts about Lantern Pharma
- Founded Year: 2013
- Location: Dallas (United States)
- Stage: Public
- Total Funding till date: $7.12M
- Employee Count: 30 as on Aug 31, 2026
- Investors: Bios Partners, Green Park & Golf Ventures and 3 Others
- Latest Funding Round: Grant (prize money), Jan 03, 2022, $*****
- Highlight: Public
Developer of small molecule drugs for neurodegenerative diseases. The company uses a proprietary screening technique to identify molecules capable of blocking toxic oligomeric proteins that cause the disease. It develops a pipeline for Alzheimer's, dementia, and Synucleinopathies.
Key facts about Cognition Therapeutics
- Founded Year: 2007
- Location: Pittsburgh (United States)
- Stage: Public
- Total Funding till date: $36.1M
- Employee Count: 28 as on Aug 31, 2026
- Investors: iNetworks, Dolby Family Ventures and 28 Others
- Latest Funding Round: Grant (prize money), Sep 27, 2022, $*****
- Highlight: Public
Developer of therapeutics for hard-to-treat cancer. It offers a lead drug candidate elraglusib a GSK-3β inhibitor that also modulates antitumor immunity to slow tumor growth and counteract resistance. It is used for the treatment of melanoma, pediatric cancer, pancreatic cancer, and others.
Key facts about Actuate Therapeutics
- Founded Year: 2015
- Location: Fort Worth (United States)
- Stage: Public
- Total Funding till date: $72.2M
- Employee Count: 16 as on Aug 31, 2026
- Investors: Bios Partners, Tech Coast Angels and 4 Others
- Latest Funding Round: Post IPO, Jun 27, 2025, $*****
- Highlight: Public
Bios Partners' Year-on-Year Investment Trends
Its most recent first time investment was in Opus Genetics and most recent follow-on round was in ONL Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
2022 | 0 | 0 | 0 |
2021 | 1 | 0 | 1 |
2020 | 1 | 1 | 2 |
2019 | 3 | 3 | 6 |
2018 | 1 | 1 | 2 |
2017 | 4 | 0 | 4 |
Bios Partners' Investments by Stage
Bios Partners has made 6 investments in Series A stage with an average round size of $8.56M, 3 investments in Series B stage with an average round size of $27.1M and 1 investment in Seed stage with an average round size of $19M.Stage of entry | No. of Investments |
|---|---|
Series A | 6 |
Series B | 3 |
Seed | 1 |
Note: We have considered here, only first round of investments
Bios Partners' Investments by Sector
Bios Partners has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Artificial Intelligence - Industry Applications, Enterprise Applications and HealthTech. Notably, it has invested in 15 Enterprise (B2B) companies, 15 Tech companies, 2 Software companies and at least 2 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 10 |
High Tech | 3 |
Artificial Intelligence - Industry Applications | 1 |
Enterprise Applications | 1 |
HealthTech | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
Bios Partners' Investments by Geography
Bios Partners has made most investments in United States (10).Bios Partners' recent investments
Bios Partners has not made any investment in 2026 so far.Here are the most recent investments by Bios Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 13, 2024 | United States | Series D | 9614 | ||
Mar 08, 2023 | United States | Series C | 8311 | [+9] | |
Sep 23, 2021 | United States | Seed | 8546 | ||
Dec 22, 2020 | United States | Series B | 6628 | ||
Sep 23, 2020 | United States | Series B | 2477 |
IPOs and Publicly Listed companies in Bios Partners' Portfolio
7 of Bios Partners' portfolio companies have become public. Opus Genetics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2024 and Actuate Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $153M.Here are Bios Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 24, 2024 | Sep 23, 2021 | Seed | 3232 | |
Aug 13, 2024 | Aug 28, 2018 | Series A | 2563 | |
Jun 16, 2023 | Mar 17, 2017 | Series A | 7387 | |
Oct 08, 2021 | - | - | 2547 | |
Jul 30, 2021 | - | - | 2571 |
Acquired companies in Bios Partners' Portfolio
2 companies from Bios Partners' portfolio have been acquired. The most recent acquisition was Lung Therapeutics in Oct 2023 by Aileron Therapeutics for $*****.Here are Bios Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 31, 2023 | May 18, 2017 | Series B | 6859 | |
Dec 20, 2016 | - | - | 3933 |
Team profile of Bios Partners
Bios Partners has a team of 10 members including 5 Partners and 3 Principals located in United States. Bios Partners' team does not sit on the board of any company as of now.Here is a list of all team members in Bios Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Dallas | - | ||
Partner | Fort Worth | - | ||
Partner | Dallas | - | ||
Partner | Fort Worth | - | - | |
Partner | Great Falls | - | - | |
Principal | Fort Worth | - | ||
Principal | Fort Worth | - | ||
Principal | Dallas | - |
Co-investors of Bios Partners
Over the past 9 years, 75 investors have co-invested in Bios Partners's portfolio companies. This includes only funds.
- Invested before Bios Partners: HHS, Breakout Labs and 19 others have invested in rounds before Bios Partners. There are 4 companies where HHS has invested before Bios Partners and 2 companies where Breakout Labs has invested before Bios Partners.
- Top Co-investors of Bios Partners: 18 investors entered a company along with Bios Partners. These include investors like DEFTA Partners (2 companies).
- Invested after Bios Partners: A total of 36 investors have invested in Bios Partners's portfolio after their investments. Top Investors include Defense.gov (2 companies), Hatteras Venture Partners (1 company) and Orlando Health (1 company).
Recent News related to Bios Partners
•
ONL Therapeutics Closes $65 Million in Oversubscribed Series D FinancingForexTV•Sep 13, 2024•ONL Therapeutics, Johnson & Johnson Innovation, Bios Partners, Novartis Venture Fund and 1 other
•
Durham startup Opus Genetics raises $4.5MWRAL TechWire•Jun 29, 2023•Opus Genetics, Bios Partners, Foundation Fighting Blindness
•
ONL Therapeutics closes first tranche of financing for trial of ONL1204clinicaltrialsarena.com•Mar 09, 2023•ONL Therapeutics, Bios Partners, Alpine Visionary Venture, Visionary Ventures and 5 others
•
ONL Therapeutics Closes 2nd Tranche of $46.9M Series B FinancingFinSMEs•Jan 13, 2022•ONL Therapeutics, Bios Partners, Johnson & Johnson Innovation, Kaitai Capital Management and 4 others
•
Ocular gene therapy biotech launches with $19M seed fundingBioPharma-Reporter•Sep 23, 2021•Opus Genetics, The Manning Family Foundation, Bios Partners
•
•
Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company AzitraBusiness Wire•Oct 15, 2020•Azitra, Bayer, Connecticut Innovations, Bios Partners
•
Actuate Therapeutics gathers $6.5 mlnPE Hub•Nov 12, 2019•Actuate Therapeutics, Bios Partners, Kairos Ventures, DEFTA Partners
•
Azitra Completes $14 Million Series A FinancingBusiness Wire•Oct 15, 2019•Azitra, KdT Ventures, Bios Partners, Connecticut Innovations and 1 other
•
